(Q37005419)

17 August 2017

0 references

1 reference

title

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials (English)

1 reference

17 August 2017

0 references

5

Arne Astrup

0 references

Henning Bliddal

series ordinal

4

object named as

Henning Bliddal

1 reference

17 August 2017

Robin Christensen

1

1 reference

17 August 2017

Pernelle Kruse Kristensen

series ordinal

2

1 reference

17 August 2017

Else Marie Bartels

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

370

1 reference

17 August 2017

9600

1 reference

17 August 2017

1706-1713

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

17 August 2017

1 reference

7 January 2021

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Endocannabinoid control of food intake and energy balance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

A Survey of Exact Inference for Contingency Tables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Meta-analysis: formulating, evaluating, combining, and reporting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Advanced methods in meta-analysis: multivariate approach and meta-regression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Meta-analysis, Simpson's paradox, and the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

How should meta-regression analyses be undertaken and interpreted?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Rimonabant for overweight or obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Long-term pharmacotherapy for obesity and overweight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Depression in association with severe obesity: changes with weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Psychosocial aspects of obesity and obesity surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Association of Cardiovascular Risk Factors and Disease With Depression in Later Life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Meta-analysis of continuous outcome data from individual patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961721-8

7 January 2021

10.1016/S0140-6736(07)61721-8

Identifiers

DOI

1 reference

17 August 2017

1 reference